Nav: Home

Drug-delivering device streamlines tuberculosis treatment in pigs

March 13, 2019

Scientists have created a retrievable, wire-like device that safely resides in the stomach and releases large dosages of drugs over several weeks. The new delivery system, which was successfully tested in pigs, could help patients in remote and underserved geographic areas adhere to drug treatments for infectious diseases such as tuberculosis (TB) that are currently treated with burdensome amounts of oral medications. TB represents one of the most widespread and devastating infectious diseases today, causing approximately 10 million cases worldwide in 2017. Most cases of TB can be effectively treated with oral antibiotics, but most therapies involve multiple drugs administered in large doses for up to several months. (An average 60 kg patient requires 3.3 grams of antibiotics a day.) Following such treatment regimens can be challenging for patients (previous research reports that 50% of patients experience difficulty sticking to treatment recommendations), especially in developing regions that lack adequate healthcare resources. As a result, poor patient adherence to treatments has become a major contributor to treatment failure and the emergence of drug-resistant TB strains. To meet the need for a more practical delivery system, Malvika Verma and colleagues developed a new platform consisting of bead-like drug pills housed on a flexible wire that can be deployed to the stomach through the esophagus in 60 seconds. The researchers studied their device in healthy pigs and found that it safely released the standard TB antibiotics rifampicin over one week and doxycycline hyclate over four weeks, and was easily retrieved via a nasogastric tube after the treatment was completed. Importantly, a questionnaire of 111 TB health care providers and 300 patients with TB in India showed that a long-term nasogastric drug delivery system was considered feasible on the ground, and an established model predicted that such a device could result in over $8,000 in savings per patient.

American Association for the Advancement of Science

Related Tuberculosis Articles:

Old target, new mechanism for overcoming tuberculosis resistance
In strains of tuberculosis that have developed drug resistance mutations, researchers have identified a secondary pathway that can be activated to reinstate drug sensitivity.
Researchers use tiny 3-D spheres to combat tuberculosis
Researchers at the University of Southampton have developed a new 3-D system to study human infection in the laboratory.
How the tuberculosis vaccine may protect against other diseases
The tuberculosis vaccine is well known to help protect against other infectious diseases, as well as cancer, but the exact mechanisms have not been clear.
Tuberculosis bacteria find their ecological niche
An international team of researchers have isolated and analyzed genetically tuberculosis bacteria from several thousand patients from over a hundred countries.
Tuberculosis and HIV co-infection
The HIV virus increases the potency of the tuberculosis bacterium (Mtb) by affecting a central function of the immune system.
Scientists explain why Russian tuberculosis is the most infectious
Scientists conducted a large-scale analysis of the proteins and genomes of mycobacterium tuberculosis strains that are common in Russia and countries of the former Soviet Union and found features that provide a possible explanation for their epidemiological success.
Tuberculosis elimination at stake
New data released by the European Centre for Disease Prevention and Control and WHO/Europe show that an estimated 340,000 Europeans developed tuberculosis in 2014, corresponding to a rate of 37 cases per 100,000 population.
Curcumin may help overcome drug-resistant tuberculosis
New research indicates that curcumin -- a substance in turmeric that is best known as one of the main components of curry powder -- may help fight drug-resistant tuberculosis.
Stopping tuberculosis requires new strategy
Unless there is a major shift in the way the world fights tuberculosis -- from a reliance on biomedical solutions to an approach that combines biomedical interventions with social actions -- the epidemic and drug resistance will worsen, say researchers at Harvard T.H.
Tulane researchers working on new tuberculosis vaccine
Researchers at the Tulane National Primate Research Center are leading efforts to find a new vaccine for tuberculosis, one of the world's deadliest diseases.

Related Tuberculosis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".